Compagnie Lombard Odier SCmA’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-560
| Closed | -$20K | – | 605 |
|
|
2023
Q2 | $20K | Hold |
560
| – | – | ﹤0.01% | 481 |
|
|
2023
Q1 | $19.9K | Hold |
560
| – | – | ﹤0.01% | 518 |
|
|
2022
Q4 | $20K | Hold |
560
| – | – | ﹤0.01% | 569 |
|
|
2022
Q3 | $16K | Hold |
560
| – | – | ﹤0.01% | 541 |
|
|
2022
Q2 | $30K | Hold |
560
| – | – | ﹤0.01% | 489 |
|
|
2022
Q1 | $30K | Hold |
560
| – | – | ﹤0.01% | 492 |
|
|
2021
Q4 | $31K | Hold |
560
| – | – | ﹤0.01% | 549 |
|
|
2021
Q3 | $27K | Sell |
560
-320
| -36% | -$16.1K | ﹤0.01% | 545 |
|
|
2021
Q2 | $44K | Hold |
880
| – | – | ﹤0.01% | 503 |
|
|
2021
Q1 | $39K | Hold |
880
| – | – | ﹤0.01% | 535 |
|
|
2020
Q4 | $40K | Hold |
880
| – | – | ﹤0.01% | 463 |
|
|
2020
Q3 | $41K | Hold |
880
| – | – | ﹤0.01% | 398 |
|
|
2020
Q2 | $45K | Sell |
880
-3,600
| -80% | -$185K | ﹤0.01% | 384 |
|
|
2020
Q1 | $213K | Buy |
4,480
+880
| +24% | +$46.9K | 0.01% | 237 |
|
|
2019
Q4 | $211K | Sell |
3,600
-3,600
| -50% | -$200K | 0.01% | 245 |
|
|
2019
Q3 | $384K | Hold |
7,200
| – | – | 0.02% | 197 |
|
|
2019
Q2 | $360K | Hold |
7,200
| – | – | 0.01% | 204 |
|
|
2019
Q1 | $376K | Sell |
7,200
-2,800
| -28% | -$140K | 0.02% | 224 |
|
|
2018
Q4 | $478K | Hold |
10,000
| – | – | 0.02% | 200 |
|
|
2018
Q3 | $503K | Sell |
10,000
-2,800
| -22% | -$142K | 0.02% | 206 |
|
|
2018
Q2 | $645K | Hold |
12,800
| – | – | 0.02% | 185 |
|
|
2018
Q1 | $625K | Sell |
12,800
-1,600
| -11% | -$74.5K | 0.02% | 202 |
|
|
2017
Q4 | $638K | Buy |
14,400
+7,200
| +100% | +$333K | 0.01% | 267 |
|
|
2017
Q3 | $365K | Sell |
7,200
-66
| -0.9% | -$3.35K | 0.01% | 298 |
|
|
2017
Q2 | $392K | Hold |
7,266
| – | – | 0.01% | 296 |
|
|
2017
Q1 | $382K | Sell |
7,266
-40,800
| -85% | -$2.07M | 0.01% | 313 |
|
|
2016
Q4 | $2.31M | Buy |
48,066
+7,200
| +18% | +$356K | 0.07% | 174 |
|
|
2016
Q3 | $2.2M | Sell |
40,866
-1,600
| -4% | -$87.7K | 0.06% | 178 |
|
|
2016
Q2 | $2.3M | Sell |
42,466
-892
| -2% | -$47K | 0.07% | 179 |
|
|
2016
Q1 | $2.2M | Buy |
43,358
+37,372
| +624% | +$1.86M | 0.07% | 155 |
|
|
2015
Q4 | $303K | Sell |
5,986
-320
| -5% | -$16.3K | 0.01% | 404 |
|
|
2015
Q3 | $302K | Buy |
6,306
+2,298
| +57% | +$120K | 0.01% | 351 |
|
|
2015
Q2 | $209K | Buy |
4,008
+260
| +7% | +$14.6K | 0.01% | 428 |
|
|
2015
Q1 | $217K | Buy |
+3,748
| New | +$215K | 0.01% | 471 |
|
|
2014
Q1 | – | Sell |
-2,400
| Closed | -$160K | – | 878 |
|
|
2013
Q4 | $160K | Buy |
+2,400
| New | +$156K | 0.01% | 570 |
|
Other funds holding GSK
JEST
Compagnie Lombard Odier SCmA's GSK Position: Q3 2023 in Review
Compagnie Lombard Odier SCmA sold out of GSK (GSK) in Q3 2023, closing a stake of 560 shares — an estimated $20K sold.
Compagnie Lombard Odier SCmA first reported a position in GSK in Q4 2013 and held it in 35 quarters. The position peaked at $2.31M in Q4 2016. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.
- Compagnie Lombard Odier SCmA reported no remaining GSK position as of Q3 2023 after selling out during the quarter.
- Compagnie Lombard Odier SCmA sold 560 GSK shares in Q3 2023, an estimated $20K.
- Compagnie Lombard Odier SCmA first reported a position in GSK in Q4 2013 and held it in 35 quarters.
- Compagnie Lombard Odier SCmA's GSK position peaked at $2.31M in Q4 2016.
- 846 funds tracked by Wall St. Rank held GSK as of Q3 2023.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2023, filed 23 Oct 2023.